F.D.A. Speeds Review of Gene Therapies, Vowing to Target Rogue Clinics

November 20, 2017

(New York Times) – The Food and Drug Administration on Thursday issued new guidelines to speed the introduction of treatments involving human cells and tissues, including gene therapy. But the agency also said it would crack down on rogue clinics offering dangerous or unproven versions of those treatments. The therapies aimed at diseases like leukemia are known as regenerative medicine and have quickly grown into a booming industry worldwide.

Recommended Reading